United States: Recent Guidance Issued On Mental Health Parity And Tobacco Cessation Programs

Last Updated: February 23 2017
Article by Lori Jones

Below is an article recently published by the Employee Benefit Plan Review. Although issued under the Obama administration, the guidance on the MHPAEA is likely to remain relevant given the bipartisan support for mental health legislation enacted in 2016. The future of the ACA and, specifically, free preventive services such as tobacco cessation is difficult to predict at this time.

On October 27, 2016, the Departments of Labor (DOL), Health and Human Services (HHS) and the Treasury (collectively, the Departments) issued FAQs regarding (i) additional guidance for compliance under the Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA), and (ii) the scope of tobacco cessation services, which must be provided without cost under the Affordable Care Act (ACA).

MHPAEA GUIDANCE

Disclosures Required of Plans and Issuers

The MHPAEA and the regulations thereunder require that group health plans and health insurance issuers impose no greater financial requirements and treatment limitations on mental health or substance use disorder benefits than the predominant requirements and limitations that apply to substantially all medical/surgical benefits under the plans or policies.

The MHPAEA requires that a plan or issuer disclose the criteria for medical necessity determinations. In the case of plans subject to ERISA, plans are required to provide participants, upon request, with information regarding the factors used to apply a nonquantitative treatment limitation with respect to both mental health and substance use disorder benefits as well as medical/surgical benefits.

In the recent guidance, the Departments request comments on the following questions with respect to the required disclosures:

  • Would model forms whereby participants can request information be helpful? If so, what should the model forms request (e.g., a list of documents that a participant or the participant's representative could request) and what types of model forms should be issued (e.g., forms for information about medical necessity criteria or forms for information relating to the determination of usual, customary, or reasonable charges)?
  • Would model forms to be used by States as part of their review of issuers be helpful and what information should the model forms include?
  • Are there any other steps the Department can take to improve or simplify the disclosure?
  • Are there any steps to improve State examinations or Federal oversight of MHPAEA compliance?

All comments were due January 3, 2017.

Assistance in Obtaining Plan Documents and External Review

Sometimes participants have difficulty obtaining plan documents to prove a MHPAEA violation. In the recent guidance, the Departments note that there is a Parity Consumer Web Portal through which a participant can identify the appropriate Federal or State agency that can assist in obtaining plan documents or understanding information provided by a plan or issuer. The link is www.hhs.gov/mental-health-and-addiction-insurance-help. The Departments also remind participants that, in the event of a benefit denial, participants can seek an external review after exhausting internal appeals.

Financial and Quantitative Treatment Limitations

A plan or policy violates the MHPAEA if it imposes financial requirements (e.g., copayment or coinsurance) or quantitative treatment limitations (e.g., a day or visit limitation) on mental health or substance use disorder benefits that do not apply to at least 2/3 of medical/surgical benefits. Generally, a plan or policy issuer is permitted to use any reasonable method in making this determination, including a reasonable projection of future claims costs based on existing claims data for the plan. However, if there is not enough claims data, or a plan significantly changes its benefit package, or there is a significant workforce change, the use of existing claims data may not be a reasonable method.

In the recent guidance, the Departments clarify that, if a qualified actuary certifies that the plan or issuer does not have sufficient claims data, it is permissible to use data from similarly structured products or plans with similar demographics. It is important that plans and issuers document the assumptions applied in choosing a data set and making projections.

Nonquantitative Treatment Limitations

A plan or policy violates the MHPAEA if a nonquantitative treatment limitation is applied more stringently to mental health or substance use disorder benefits that it is to medical/surgical benefits. Nonquantitative treatment limitations include medical necessity standards, including requirements to obtain prior authorization. The MHPAEA regulations provide that requirements to obtain prior authorization may be required for some but not all mental health and substance use disorder benefits as well as some but not all medical/surgical benefits. However, the FAQs clarify that it is a violation of the MHPAEA to require an in-person examination prior to authorizing admission to an inpatient, in-network facility for a mental health condition if prior authorization for all medical and surgical inpatient, in-network admissions only requires authorization over the phone without an in-person examination. 

In addition, the FAQs clarify that it is not permissible to require an intensive outpatient program prior to authorizing coverage of inpatient treatment of mental health or substance use disorder benefits, even though there are similar requirements for medical/surgical benefits, if there are no such outpatient programs to treat substance use disorder in the participant's geographic area. Such requirements are often referred to as "fail-first" requirements. The Departments indicate that, if the lack of access to fail-first programs exists only with respect to mental health or substance use disorder benefits, then the requirement, in operation, is applied more stringently to the mental health and substance use disorder benefits.

Medication Treatment for Opioid Use Disorder

Three medications are approved by the FDA for use in treatment for opioid use disorder, including buprenorphine. The FAQs clarify that requiring prior authorization for buprenorphine due to safety risks associated with the drug is not permitted under the MHPAEA if prior authorization is not required for drugs to treat medical/surgical conditions that have similar safety risks. The FAQs state that, in such case, the prior authorization requirement is being applied more stringently to drugs used for mental health and substance use benefits and, therefore, violates the MHPAEA.

The FAQs also clarify that requiring a participant to satisfy a non-pharmacological fail-first requirement, such as counseling, before it will authorize coverage for buprenorphine is not permissible if the plan does not impose a similar fail-first requirement on prescription drugs for medical surgical conditions. The FAQs state that a fail-first requirement on coverage for buprenorphine for opioid use disorder cannot be imposed unless such a fail-first requirement is comparable to, and applied no more stringently than, the fail-first requirements for medical surgical benefits.

The Departments note that, if a plan states that it follows nationally recognized treatment guidelines for setting prior authorization requirements for prescription drugs, it may not require prior authorization for buprenorphine/naloxone at each 30-day refill for opioid use disorder since it is not consistent with nationally recognized treatment guidelines. Alternatively, if a plan follows guidelines established by Pharmacy and Therapeutics committees in deciding how to cover prescription drugs, it is necessary to determine whether the relevant committee is comprised of comparable experts for mental health and substance use disorder conditions as compared to experts for medical and surgical conditions and how such experts reviewed nationally recognized treatment guidelines in setting authorization guidelines for mental health and substance use disorder conditions versus medical and surgical conditions. The FAQs note that a prior authorization for buprenorphine/naloxone that is limited to 30 days could be inconsistent with authorization practices for chronic medical and surgical conditions since authorization for prescription drugs intended to treat a medical or surgical condition is typically appropriate at six or 12 months (absent a comparable 30-day restriction for medical/surgical conditions).

Finally, the FAQs note that exclusion of a court-ordered treatment for substance use disorder is not permissible if a plan does not exclude a court-ordered treatment for medical or surgical conditions. However, such an exclusion is permissible if a plan applies a medical necessity criteria to all court-ordered treatment, provided that participants have the right to challenge a benefit denial and request an external medical necessity review.

ACA GUIDANCE

Preventive Services for Tobacco Cessation

  In the FAQs the Departments note that they have received numerous questions regarding the type of tobacco cessation programs that must be offered in order to comply with the ACA. In FAQs issued May 2, 2014, the Departments indicated that plans and issuers will be deemed to be in compliance with the requirement to cover tobacco use counseling and interventions if they comply with the 2009 recommendations issued by the United States Preventive Services Task Force (USPSTF). However, the USPSTF updated its recommendations regarding tobacco cessation on September 22, 2015. For example, the USPSTF now recommends both pharmacotherapy and behavioral interventions and further indicates that a combination of such interventions is the most effective approach. The September 22, 2015, USPSTF recommendations also list seven FDA-approved medications for treating tobacco dependence, including nicotine patches, nicotine lozenges, nicotine gum, and four prescription medications.

Regulations issued under the ACA define preventive services in accordance with USPSTF recommendation and require that updated USPSTF recommendations be covered as preventive services, without cost-sharing, effective as of the plan year that begins on or after one year from the issue date of such recommendations. Accordingly, plans and issuers have asked whether compliance with the September 22, 2015, USPSTF recommendations is required for plan years commencing on or after September 22, 2016.

In lieu of providing immediate guidance, the Departments request comments from plans and issuers on the following questions:

  • Must all seven FDA approved medications be covered under a plan or insurance policy without cost sharing if prescribed by a health care provider, or can plans and issuers use reasonable medical management techniques to determine which medications will be covered without cost sharing?
  • Can plans and issuers use reasonable medical management techniques to (i) limit the number of quit attempts per year or the duration of the interventions required, (ii) manage the types of medications that may be covered when used in combination, or (iii) limit the types of behavioral interventions that are covered without cost sharing?

All comments were due January 3, 2017.

Reprinted with permission from Employee Benefit Plan Review - January 2017

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions